YM Biosciences has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to CYT387, its JAK1/2 inhibitor for the treatment of myelofibrosis.

Myelofibrosis is a debilitating condition in which bone marrow is replaced by scar tissue.

CYT387 is currently being investigated in an oral Phase I/II clinical study involving myelofibrosis patients at Mayo Clinic, New York.

The clinical results showed that CYT387 demonstrated promising evidence of biological activity, including significant spleen size reduction, favourable haematological changes and improvement in constitutional symptoms.

Orphan drug designation is granted to drugs that treat disease conditions affecting fewer than 200,000 patients in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.